Autoimmune diseases affect an estimated 5% to 10% of people with autoimmune thyroid disease, but diagnosis delays can run for years. A U.S. study reported a median 8.7-year diagnostic delay for celiac disease, with other conditions also showing long time-to-diagnosis windows. The economic burden is equally stark, with psoriasis costing an estimated $30.5 billion annually in the United States and rheumatoid arthritis accounting for about 4.6% of total national health expenditures.
Key Takeaways
- Up to 6.5% of adults in the United States have celiac disease (estimated prevalence)
- 2% of the U.S. population has lupus (about 1.5 million people) as estimated by the Lupus Foundation of America
- 5% of U.S. adults have Sjögren’s syndrome (approx. 4 million people) — Sjögren’s is an autoimmune disease
- $30.5 billion estimated annual cost of psoriasis in the United States (2013)
- $8.6 billion is the estimated annual economic burden of inflammatory bowel disease in the United States (2014)
- $10,660 average annual direct medical costs per patient for rheumatoid arthritis in the U.S. (mean, 2013 estimates)
- The autoimmune disease therapeutics market is projected to grow at a CAGR of 7.1% from 2024 to 2030 (forecast)
- The global rheumatoid arthritis therapeutics market size was $27.8 billion in 2023 (market estimate)
- The global psoriasis therapeutics market is projected to reach $26.9 billion by 2030 (forecast)
- Adalimumab had global sales of about $21.6 billion in 2023 (leading autoimmune biologic)
- Rituximab achieved $4.9 billion in global sales in 2023 (autoimmune use, e.g., RA, lupus)
- Ustekinumab generated $7.2 billion in global sales in 2023 (psoriasis/IBD autoimmune indications)
- A U.S. study found a median 5.5-year delay from symptom onset to diagnosis for rheumatoid arthritis (time-to-diagnosis metric)
- A U.S. study reported a median 8.7-year diagnostic delay for celiac disease (time-to-diagnosis metric)
- In lupus, the median time to diagnosis has been reported at 4 years in population studies (care pathway metric)
Autoimmune diseases affect millions in the US and drive major costs, with delays in diagnosis common.
Related reading
01 · Category
Disease Burden5 stats
01
Up to 6.5% of adults in the United States have celiac disease (estimated prevalence)
02
2% of the U.S. population has lupus (about 1.5 million people) as estimated by the Lupus Foundation of America
03
5% of U.S. adults have Sjögren’s syndrome (approx. 4 million people) — Sjögren’s is an autoimmune disease
04
Estimated prevalence of autoimmune thyroid disease is 5% to 10% of the population in many populations (commonly cited range)
05
0.24% annual incidence of type 1 diabetes globally (children), reflecting autoimmune beta-cell destruction incidence at the population level
Interpretation
Disease Burden Interpretation
For the Disease Burden category, the figures show that autoimmune conditions are widespread at the population level, with prevalence reaching as high as about 6.5% for celiac disease and 5% to 10% for autoimmune thyroid disease, while even the global annual incidence of type 1 diabetes is 0.24% among children.
02 · Category
Economic Impact7 stats
01
$30.5 billion estimated annual cost of psoriasis in the United States (2013)
02
$8.6 billion is the estimated annual economic burden of inflammatory bowel disease in the United States (2014)
03
$10,660average annual direct medical costs per patient for rheumatoid arthritis in the U.S. (mean, 2013 estimates)
04
$2,034average incremental annual costs per patient associated with Crohn’s disease in the U.S. (mean incremental estimate)
05
$2.5 billion annual U.S. healthcare costs attributable to lupus (direct medical costs estimate)
06
4.6% of total national health expenditures in the U.S. are attributed to rheumatoid arthritis and related diseases (estimate from 2015-2017 modeling)
07
$28.0 billion (2020) expected global autoimmune disease therapeutics spending (projected market value for autoimmune treatments)
Interpretation
Economic Impact Interpretation
In the Economic Impact framing, autoimmune diseases like psoriasis, inflammatory bowel disease, rheumatoid arthritis, Crohn’s disease, and lupus impose a sustained financial strain, with psoriasis alone costing an estimated $30.5 billion annually in the U.S. while rheumatoid arthritis and related diseases account for 4.6% of all national health expenditures.
03 · Category
Market Size10 stats
01
The autoimmune disease therapeutics market is projected to grow at a CAGR of 7.1% from 2024 to 2030 (forecast)
02
The global rheumatoid arthritis therapeutics market size was $27.8 billion in 2023 (market estimate)
03
The global psoriasis therapeutics market is projected to reach $26.9 billion by 2030 (forecast)
04
The global inflammatory bowel disease therapeutics market was valued at $6.5 billion in 2023 and is projected to reach $10.7 billion by 2030 (forecast)
05
The global celiac disease treatment market is projected to grow to $7.3 billion by 2030 (forecast)
06
The global systemic lupus erythematosus (SLE) therapeutics market is projected to reach $4.9 billion by 2030 (forecast)
07
The global multiple sclerosis therapeutics market is projected to reach $37.2 billion by 2030 (forecast)
08
The autoimmune disease diagnostics market is projected to grow at a CAGR of 5.5% from 2024 to 2030 (forecast)
09
The global precision medicine market for autoimmune disease applications is projected to exceed $20 billion by 2030 (forecast)
10
The global immunoassay market size is forecast to reach $14.8 billion by 2030 (relevant to autoimmune diagnostics)
Interpretation
Market Size Interpretation
The autoimmune disease therapeutics market is set to expand steadily with a 7.1% CAGR from 2024 to 2030, while major segments already reach large valuations such as $27.8 billion for rheumatoid arthritis in 2023 and are projected to grow to $26.9 billion for psoriasis by 2030, underscoring strong market size momentum across autoimmune conditions.
More related reading
04 · Category
Drug Adoption9 stats
01
Adalimumab had global sales of about $21.6 billion in 2023 (leading autoimmune biologic)
02
Rituximab achieved $4.9 billion in global sales in 2023 (autoimmune use, e.g., RA, lupus)
03
Ustekinumab generated $7.2 billion in global sales in 2023 (psoriasis/IBD autoimmune indications)
04
Secukinumab reported $6.7 billion in global sales in 2023 (psoriasis/psoriatic arthritis autoimmune indications)
05
Vedolizumab had $6.0 billion in global sales in 2023 (IBD autoimmune indication)
06
Janus kinase (JAK) inhibitors accounted for $9.6 billion of global rheumatoid arthritis drug sales in 2023 (class share estimate)
07
In a large U.S. claims study, 55% of rheumatoid arthritis patients received at least one biologic DMARD within 5 years of diagnosis (treatment pathway metric)
08
About 35% of psoriasis patients in a claims-based analysis used biologic therapies at some point during follow-up (treatment adoption metric)
09
In inflammatory bowel disease, about 20% of patients progressed to biologic therapy within 2 years of diagnosis (real-world treatment adoption estimate)
Interpretation
Drug Adoption Interpretation
In the drug adoption landscape, autoimmune treatments are clearly scaling fast with major brands reaching $21.6 billion for adalimumab in 2023 while JAK inhibitors alone accounted for $9.6 billion of global rheumatoid arthritis drug sales the same year, showing strong uptake across both biologics and newer oral options.
05 · Category
Care Pathways10 stats
01
A U.S. study found a median 5.5-year delay from symptom onset to diagnosis for rheumatoid arthritis (time-to-diagnosis metric)
02
A U.S. study reported a median 8.7-year diagnostic delay for celiac disease (time-to-diagnosis metric)
03
In lupus, the median time to diagnosis has been reported at 4 years in population studies (care pathway metric)
04
In Sjögren’s syndrome, median time to diagnosis has been reported around 3.9 years (care pathway metric)
05
In inflammatory bowel disease, about 25% of patients had a delay of more than 6 months between symptom onset and diagnosis (time-to-diagnosis metric)
06
Approximately 40% of psoriatic arthritis patients are diagnosed with disease after a delay of more than 2 years (time-to-diagnosis metric)
07
The 2021 ACR guideline recommends methotrexate as first-line therapy for many rheumatoid arthritis patients unless contraindicated (treatment pathway metric)
08
Early intervention in rheumatoid arthritis within 12 weeks is associated with improved outcomes in observational cohorts (early-care metric)
09
In a real-world study, patients achieving low disease activity within 6 months were more likely to maintain better outcomes at 2 years (outcomes metric)
10
In a population study, about 60% of ulcerative colitis patients required escalation beyond 5-ASA within 5 years (step-up care metric)
Interpretation
Care Pathways Interpretation
Across autoimmune diseases, care pathways often involve long waits, with median diagnostic delays of 3.9 years for Sjögren’s syndrome and 4 years for lupus, while in inflammatory bowel disease about 25% wait over 6 months and roughly 40% of psoriatic arthritis patients are diagnosed more than 2 years after symptoms begin.
06 · Category
Risk Factors9 stats
01
Cigarette smoking increases risk of rheumatoid arthritis (meta-analysis estimate: current smoking vs never smoking HR ~1.8)
02
Smoking is associated with roughly a 2-fold increased risk of developing rheumatoid arthritis compared with never smokers (systematic review estimate)
03
Obesity increases risk of developing psoriatic disease and psoriasis; meta-analysis reports odds ratio ~1.5 (BMI-related risk metric)
04
Alcohol intake is associated with increased risk of autoimmune thyroid disease; meta-analysis reports pooled RR ~1.4
05
Family history is a key risk factor for celiac disease; first-degree relatives have an estimated risk of ~10% (relative risk metric)
06
HLA-DQ2/DQ8 positivity is present in approximately 95% of individuals with celiac disease (genetic risk marker prevalence)
07
Female sex is overrepresented in autoimmune diseases; rheumatoid arthritis occurs in women ~2–3 times more often than men (epidemiologic risk metric)
08
Vitamin D insufficiency is common; in U.S. adults, about 42% have vitamin D levels below 20 ng/mL (deficiency metric relevant to immune regulation)
09
Chronic stress is associated with immune dysregulation; a meta-analysis reports moderate associations between psychological stress and inflammation markers (effect size metric)
Interpretation
Risk Factors Interpretation
Across autoimmune risk factors, lifestyle and genetics show clear signals, with smoking nearly doubling rheumatoid arthritis risk (about HR 1.8 or roughly 2-fold), obesity raising psoriatic disease and psoriasis risk by around 1.5, and celiac disease driven strongly by genetics such as HLA-DQ2/DQ8 present in about 95% of cases and an estimated 10% risk in first-degree relatives.
report visual · Breakdown
Autoimmune disease snapshot: how common and how much it costs
Common prevalence varies across autoimmune diseases, while economic burden spans billions annually—highlighting both health impact and healthcare spending.
5%
5% of U.S. adults have Sjögren’s syndrome (approx. 4 million people) — Sjögren’s is an autoimmune disease
95%
HLA-DQ2/DQ8 positivity is present in approximately 95% of individuals with celiac disease (genetic risk marker prevalenc
source-verifiedncbi.nlm.nih.gov · pubmed.ncbi.nlm.nih.gov
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Samuel Norberg. (2026, February 13). Autoimmune Disease Statistics. Gitnux. https://gitnux.org/autoimmune-disease-statistics
MLA
Samuel Norberg. "Autoimmune Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/autoimmune-disease-statistics.
Chicago
Samuel Norberg. 2026. "Autoimmune Disease Statistics." Gitnux. https://gitnux.org/autoimmune-disease-statistics.
Sources & references
50 datasets cited across this report · attribution is report-level
+37 additional datasets cited (not shown individually)